NCT05656248 · OUTCOME

Event-free Survival (EFS) of Patients Who Received One or Two Courses of CPX-351 Followed by HSCT

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms · Source last updated 2026-10-15

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: 3 years from study entry

What was measured

We will use the Kaplan-Meier method to estimate event-free survival. We define EFS as the time elapsed from protocol enrollment to death, relapse, discontinuation of therapy due to excessive toxicity or resistant disease, or development of an additional malignancy and censor times for patients free of these events at last follow-up.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: We will use the Kaplan-Meier method to estimate event-free survival. We define EFS as the time elapsed from protocol enrollment to death, relapse, discontinuation of therapy due to excessive toxicity or resistant disease, or development of an additional malignancy and censor times for patients free of these events at last follow-up.
reporting Status: NOT_POSTED
time Frame: 3 years from study entry
title: Event-free Survival (EFS) of Patients Who Received One or Two Courses of CPX-351 Followed by HSCT
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice